Roman Vintfeld, chief executive officer of InterFACETM, a nationally recognized talent marketing company based in New Jersey, announced the acquisition of Industry Model and Talent Studios, a model and talent development center, also based in New Jersey. The merged company will be called InterFACETM and will be located in new headquarters at 15 Kennedy Boulevard, East Brunswick, New Jersey. Through the purchase of Industry Model, InterFACE will be the leading talent marketing company for entertainment on the East Coast.
InterFACE has expanded its market share and marketing activities and will uphold and Cheap Patek Philippe Watches Industry Model and Talent Studio's existing client relationships. Mr. Vintfeld states, "We are working with the clients of Industry Model offering them even more efficient talent marketing and promotional opportunities. During our years in business, we have helped many talented people get their start in entertainment as models, actors, singers and performers and have created strong relationships with industry professional that are equally beneficial to talent and to agents, personal managers, casting directors and music producers."
InterFACE is led by Mr. Vintfeld, Mitch Rubin, chief financial officer/chief operating office and Danielle Vintfeld, vice president, in new 12,000 square foot New Jersey offices. The company will employ 500 with 200 employees based in East Brunswick. Additionally, InterFACE has announced the opening of their Florida regional headquarters at 150 East Palmetto Park Road, Suite 175, Boca Raton, Florida. There will be approximately 50 employees in that 8,000 square foot office.
The ribbon cutting to officially open the Boca center will take place on Cheap Porsche Design Watches 28, from 10:00AM to 12:00 PM, and will feature special guest Mayor Susan Whelchel who with Roman Vintfeld and other InterFACE executives will cut the ribbon. The event is open to the public.
"We are excited to bring our talent marketing services to this thriving area," stated Vintfeld. "In the ever more competitive entertainment and fashion industries, for models, actor, singers and performers, InterFACE believes that we provide direction and support to aspiring talent in a cost effective and productive manner."
Executives for this regional headquarters are Eric Bernstein, vice president of operations, Sioban Shariat, vice president of development and marketing and Janixx Parisi, executive director of development and marketing. The New England area is serviced by the InterFACE office in Connecticut. InterFACE presently has 10,000 clients ranging from children to seniors.
InterFACE assists entertainment talent in creating online high resolution composite Cheap Replica Chanel Watches and headshots for modeling, music, acting and other entertainment talents. Once the entertainment marketing package is completed, InterFACE harnesses the power of technology to market its talent pool to industry professionals worldwide on InterFACE Pages, a unique, user-friendly online portal.
In industries like fashion and entertainment, where barriers to entry are high and competition is fierce, InterFACE strives to provide aspiring actors, singers, musicians, models and other entertainment talent with the right tools to market themselves and entertainment industry professionals with a cost-effective and convenient way to scout a talent pool that meets their needs.
Regeneron Pharmaceuticals, Inc. filed the patent application on April 24, 2003. The patent application number is 00629/DELNP/2003 A. The international classification number is C12N15/85.
According to the Controller General of Patents, Designs & Trade Marks, "A method for Cheap Replica Rolex Watches and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous genes(s) or chromosomal locus (loci) as well as the use of these cells to genetale organising bearing; the genetic modification."
Regeneron Pharmaceuticals, Inc. (Regeneron) (Public, NASDAQ:REGN) is engaged in the research, development and commercialization of therapeutics to treat human disorders and conditions. The Company's facilities are primarily located in New York. As of December 31, 2009, the Company had one marketed product: ARCALYST (rilonacept) injection for subcutaneous use, which is available for prescription in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older. Its late stage programs are rilonacept, which is being developed for the prevention and treatment of gout-Cheap Replica Ulysse Nardin Watches flares; VEGF Trap-Eye, which is being developed in eye diseases using intraocular delivery in collaboration with Bayer HealthCare LLC, and aflibercept (VEGF Trap), which is being developed in oncology in collaboration with the sanofi-aventis Group.